Soleno TherapeuticsSLNO
SLNO
About: Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
Employees: 92
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
212% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 25
100% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 24
16% more funds holding
Funds holding: 142 [Q3] → 165 (+23) [Q4]
2% less call options, than puts
Call options by funds: $120M | Put options by funds: $123M
4% less capital invested
Capital invested by funds: $2.38B [Q3] → $2.29B (-$85M) [Q4]
2.86% less ownership
Funds ownership: 121.22% [Q3] → 118.37% (-2.86%) [Q4]
11% less funds holding in top 10
Funds holding in top 10: 9 [Q3] → 8 (-1) [Q4]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$97
29%
upside
Avg. target
$112
49%
upside
High target
$145
93%
upside
7 analyst ratings
7 positive
100%
0 neutral
0%
0 negative
0%
Guggenheim Debjit Chattopadhyay 21% 1-year accuracy 6 / 28 met price target | 29%upside $97 | Buy Maintained | 8 May 2025 |
Baird Brian Skorney 29% 1-year accuracy 7 / 24 met price target | 40%upside $105 | Outperform Maintained | 8 May 2025 |
Piper Sandler Yasmeen Rahimi 24% 1-year accuracy 5 / 21 met price target | 93%upside $145 | Overweight Maintained | 24 Apr 2025 |
HC Wainwright & Co. Raghuram Selvaraju 36% 1-year accuracy 110 / 305 met price target | 33%upside $100 | Buy Reiterated | 15 Apr 2025 |
Stifel James Condulis 67% 1-year accuracy 2 / 3 met price target | 44%upside $108 | Buy Maintained | 28 Mar 2025 |
Financial journalist opinion
Based on 4 articles about SLNO published over the past 30 days
Neutral
Seeking Alpha
1 week ago
Soleno Therapeutics, Inc. (SLNO) Q1 2025 Earnings Call Transcript
Soleno Therapeutics, Inc. (NASDAQ:SLNO ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors Anish Bhatnagar - Chief Executive Officer Meredith Manning - Chief Commercial Officer Jim Mackaness - Chief Financial Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Debjit Chattopadhyay - Guggenheim Securities Kristen Kluska - Cantor Leland Gershell - Oppenheimer Brian Skorney - Baird James Condulis - Stifel Myriam Belghiti - LifeSci Capital Yale Jen - Laidlaw Operator Greetings, and welcome to the Soleno Therapeutics First Quarter 2025 Earnings Conference Call. At this time, note that all participants are in a listen-only mode.
Neutral
GlobeNewsWire
1 week ago
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results
REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial results for the first quarter ended March 31, 2025.
Positive
Zacks Investment Research
1 week ago
Soleno Therapeutics (SLNO) is on the Move, Here's Why the Trend Could be Sustainable
Soleno Therapeutics (SLNO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Neutral
GlobeNewsWire
3 weeks ago
Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET
REDWOOD CITY, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its first quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, May 7, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations.
Neutral
GlobeNewsWire
1 month ago
Soleno Therapeutics Announces VYKAT(TM) XR Launch
REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the U.S. commercial availability of VYKAT™ XR (diazoxide choline) extended-release tablets, the company's treatment for hyperphagia in patients four years of age and older with Prader-Willi syndrome (PWS), which was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025.
Positive
Zacks Investment Research
1 month ago
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug
Soleno's shares soar in the premarket hours following the FDA approval of Vykat XR (diazoxide choline) for treating hyperphagia in PWS patients.
Positive
Investors Business Daily
1 month ago
Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, Pulling Aardvark Higher
Soleno Therapeutics won approval for a drug that treats excessive hunger associated with a rare disease, and the biotech stock rocketed. The post Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, Pulling Aardvark Higher appeared first on Investor's Business Daily.
Positive
Benzinga
1 month ago
Soleno Therapeutics Secures FDA Approval For Its First Commercial Drug For Rare Genetic Disorder
The U.S. Food and Drug Administration (FDA) on Wednesday approved Soleno Therapeutics, Inc.'s SLNO Vykat XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome (PWS).
Neutral
GlobeNewsWire
1 month ago
Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome
First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March 26 th , at 5:30pm ET REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved VYKAT XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome (PWS).
Neutral
GlobeNewsWire
3 months ago
Soleno Therapeutics to Participate in Upcoming February Investor Conferences
REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in February:
Charts implemented using Lightweight Charts™